CanSino Biologics plans to use the public reserve fund to make up for the loss.

Kangxinuo Biotech announced that the company proposes to use the accumulated surplus to offset the cumulative losses as of December 31, 2024. According to the 2024 financial statements and audit report issued by Deloitte Huayong Accounting Firm, the parent company has accumulated losses of RMB 1.45 billion, a surplus reserve of RMB 1.18 billion, and a capital reserve of RMB 65.77 billion. It is recommended to use the surplus reserve of RMB 1.18 billion and the capital reserve of RMB 13.32 billion to offset the losses. After the plan is completed, the surplus reserve will be reduced to RMB 0, the capital reserve will be reduced to RMB 52.45 billion, and the accumulated losses will be fully offset to RMB 0.